Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 9/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853471 | 1.00 | MAPT (0.35) | MAPTKDM4EALDH1A1LMNATP53 | |
| SCHEMBL24258519 | 0.82 | PDE3B (0.41) | MAPTKDM4EALDH1A1LMNATP53 | |
| SCHEMBL29403112 | 0.80 | CREBBP (0.50) | CREBBPBRD4EP300 | |
| SCHEMBL17785637 | 0.80 | CREBBP (0.50) | CREBBPBRD4EP300 | |
| SCHEMBL31565516 | 0.78 | MAPT (0.31) | MAPTKDM4EALDH1A1LMNATP53 | |
| SCHEMBL31565360 | 0.78 | AR (0.32) | MAPTKDM4EALDH1A1LMNATP53 | |
| SCHEMBL23930103 | 0.74 | CREBBP (0.39) | CREBBPBRD4EP300 | |
| SCHEMBL30023382 | 0.74 | CREBBP (0.39) | CREBBPBRD4EP300 | |
| SCHEMBL24316742 | 0.73 | CREBBP (0.52) | MAPTCREBBPBRD4EP300 | |
| SCHEMBL30992903 | 0.73 | CREBBP (0.41) | MAPTKDM4EGAACREBBPCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2025-12-02 | — | — | US | disclosed |
| CN-115397822-B | CBP/EP300 inhibitors and uses thereof | 南京药石科技股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4140996-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-03-01 | — | — | EP | disclosed |
| CN-115397822-A | CBP/EP300 inhibitors and uses thereof | 南京药石科技股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021213521-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | 南京药石科技股份有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | EP300, CREBBP, BPTF | MAPT 2797/4885KDM4E 440/4885ALDH1A1 2314/4885 |
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | EP300, CREBBP, BPTF | MAPT 2797/4885KDM4E 440/4885ALDH1A1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.